Core Insights - The company reported a steady improvement in its overall innovation capabilities, with innovative drug revenue exceeding 6.7 billion yuan in the first three quarters of 2025, representing a year-on-year growth of 18.09% [1][2] - The company has set a target for a compound annual growth rate of 20% for innovative drug revenue from 2025 to 2027, driven by the commercialization of existing products and the approval of new products in the next 2 to 3 years [3] Financial Performance - In the first three quarters of 2025, the company achieved total revenue of 29.393 billion yuan and a net profit attributable to shareholders of 2.523 billion yuan, reflecting a year-on-year increase of 25.5% [1] R&D Investment - The company invested a total of 3.998 billion yuan in R&D in the first three quarters of 2025, marking a year-on-year increase of 2.12%, with R&D expenses in Q3 alone reaching 1.013 billion yuan, up 28.81% [3] AI Strategy - The company is integrating AI into various stages of drug development, utilizing platforms like PharmAID to enhance decision-making and efficiency in research and clinical trials [4] - The long-term goal is to create an intelligent system that spans the entire chain from R&D to operations and products, enhancing innovation capabilities and competitiveness [4] Global Operations - The company views its international strategy as a key growth engine, aiming to enhance its global R&D, production, registration, and commercialization capabilities [4][5] - In the U.S. market, the company has established a mature generic drug self-operated team and has launched 34 products as of June 30, 2025 [5] Emerging Markets - The company has built a marketing network covering over 40 countries in Africa and is progressing with local drug manufacturing projects [6] - It is also expanding its presence in emerging markets such as ASEAN and the Middle East [6] Shareholder Engagement - The company has completed its share repurchase plans for A-shares and H-shares in 2025, repurchasing a total of 14.23 million A-shares and 3.41 million H-shares, aimed at maintaining investor interests and boosting market confidence [6]

Core Insights - The company has demonstrated steady improvement in its innovation capabilities, with innovative drug revenue exceeding 6.7 billion yuan in the first three quarters of 2025, representing an 18.09% year-on-year growth [1][2] - The company aims for a compound annual growth rate of 20% in innovative drug revenue from 2025 to 2027, driven by ongoing commercialization of existing products, new product approvals, and contributions from overseas markets [3] Financial Performance - In the first three quarters of 2025, the company achieved total revenue of 29.393 billion yuan and a net profit attributable to shareholders of 2.523 billion yuan, reflecting a year-on-year increase of 25.5% [2] - The company's R&D investment reached 3.998 billion yuan in the first three quarters of 2025, marking a 2.12% increase, with Q3 R&D expenses amounting to 1.013 billion yuan, up 28.81% [4] Innovation and Product Development - The company has made significant progress with several self-developed innovative drugs, including a new indication approval for its CDK4/6 inhibitor in China for breast cancer treatment [2] - The second CAR-T product from the company has had its registration application accepted by the National Medical Products Administration for treating relapsed or refractory acute lymphoblastic leukemia [2] AI Strategy - The company is advancing its AI strategy, integrating AI into various stages of drug development to enhance efficiency and reduce early-stage R&D cycles [4][5] - The PharmAID decision-making platform has been launched to support commercial value assessment and pipeline selection, significantly improving R&D decision-making and execution efficiency [4][5] Global Operations - The company views its international strategy as a key growth driver, focusing on enhancing global R&D, production, registration, and commercialization capabilities [7] - In the U.S. market, the company has established a mature self-operated generic drug team and has launched 34 products as of June 30, 2025 [7] - The company has built a marketing network covering over 40 countries in Africa and is progressing with local drug manufacturing projects [7] Shareholder Engagement - The company has completed its A-share and H-share repurchase plans and has introduced stock option incentive plans to enhance long-term incentive mechanisms [8] - Since the beginning of 2025, the company has repurchased 14.23 million A-shares and 3.41 million H-shares, totaling approximately 348 million yuan and 47.84 million HKD, respectively [8]

Major Announcements - EVE Energy signed a procurement framework agreement with Smoore International for the continuous supply of battery cells and other products as raw materials, with actual amounts to be determined by future orders [3] - ST Huami's stock is under "double risk" warning due to an audit report expressing inability to provide an opinion for the 2024 financial report, with a recovery of 1.567 billion yuan in occupied funds [4] - Wuzhou Transportation received a regulatory warning for accounting irregularities and failure to fulfill integrity checks for executives, leading to inaccurate financial disclosures [5] - Wenfeng Co. announced that its vice president is under investigation, but this will not significantly impact the company's operations [6] - Fosun Pharma's subsidiary has had its drug included in the breakthrough therapy designation program for gastric cancer treatment, marking a significant development in its product pipeline [7][8] - Shandong Steel's subsidiary is applying for bankruptcy liquidation, which is expected to increase the parent company's net profit by 15.88 million yuan [9] - Zhouming Technology established a new subsidiary, Shenzhen Zhixian Robotics Co., with a registered capital of 50 million yuan [10] Share Buybacks and Holdings - Spring Airlines conducted its first share buyback, acquiring 35,800 shares for a total of 1.9997 million yuan [11] - Donghua Software's controlling shareholder reduced his stake by 1%, selling 10.9832 million shares [12] - Changshu Bank's executives plan to increase their holdings by at least 550,000 shares over the next six months [13] Major Contracts - Nanfeng Co. won contracts worth 45.7 million yuan and 47.17 million yuan for HVAC systems, with delivery scheduled for 2027 [14] - Huakang Clean announced a pre-bid win for a purification system project at Keqiao Future Medical Center, with a bid price of 176 million yuan [15][16] - Qinglong Pipe Industry secured a contract worth 294 million yuan for a pipe procurement project, expected to impact its performance from 2026 to 2030 [17] - China Nuclear Engineering signed new contracts totaling 123.84 billion yuan as of October, with cumulative revenue of 81.334 billion yuan [18]

Core Viewpoint - The article summarizes important announcements from various companies, providing insights for investors regarding partnerships, financial performance, and regulatory actions. Group 1: Partnerships and Agreements - EVE Energy signed a procurement framework agreement with Smoore International for the continuous supply of battery cells and other products, with the actual amounts to be determined by future orders [4] Group 2: Financial Performance and Risks - ST Huami's stock is under "double risk" warning due to an inability to express an opinion on its 2024 financial report, with 1.567 billion yuan of occupied funds recovered [5] - Shandong Steel's subsidiary Metallurgical Ecology is applying for bankruptcy liquidation, which is expected to increase the parent company's net profit by 158.8 million yuan [9] Group 3: Regulatory Actions - Wuzhou Transportation received a regulatory warning for accounting irregularities and failure to fulfill integrity checks for executives, leading to inaccurate financial disclosures [6] - Wenkang's vice president is under investigation, but the company states that this will not significantly impact its operations [7] Group 4: New Projects and Contracts - Nanfeng Co. won contracts worth 45.7 million yuan and 47.17 million yuan for HVAC systems, expected to positively impact future financial performance [14] - Huakang Clean announced a pre-bid win for a purification system project at Keqiao Future Medical Center, with a bid of 176 million yuan [16] - Qinglong Pipe Industry secured a contract worth 294 million yuan for pipe procurement, which represents 10.43% of its audited revenue for 2024 [17] - China Nuclear Engineering signed new contracts totaling 123.84 billion yuan as of October 2025, with revenue of 81.334 billion yuan [18] Group 5: Share Buybacks and Holdings - Spring Airlines conducted its first share buyback, acquiring 35,800 shares for a total of 1.9997 million yuan [11] - Donghua Software's controlling shareholder reduced his stake by 1%, now holding 10.90% of the company [12] - Changshu Bank's executives plan to increase their holdings by at least 550,000 shares over the next six months [13]

Group 1 - Moer Thread announced an issuance price of 114.28 CNY per share, with a total of 70 million shares to be publicly issued, aiming to raise 8 billion CNY, netting approximately 7.576 billion CNY after expenses [1] - EVE Energy signed a procurement framework agreement with Simo International for battery cells from 2026 to 2028, with the agreement effective until December 31, 2028, but does not specify a concrete amount [1] - Tuojing Technology's major shareholder, the National Integrated Circuit Industry Investment Fund, plans to reduce its stake by up to 3% through block trading from December 12, 2025, to March 11, 2026 [1] Group 2 - Shengyi Electronics announced that its shareholder, Dongguan Science and Technology Innovation Investment Group, plans to reduce its stake by up to 1% from December 12, 2025, to March 11, 2026, due to funding needs [2] - Deep Technology reported that it is a leading domestic high-end storage chip packaging and testing company, currently operating at full capacity in Shenzhen and Hefei, and is expanding based on customer demand [2] - Wengfeng Co. announced that its deputy general manager, Qin Guofen, is under investigation, but this matter is personal and will not significantly impact the company's operations [2] Group 3 - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology, has had its drug, Surulitinib, included in the breakthrough therapy designation for gastric cancer, with no other PD-1 monoclonal antibody approved for this indication globally [3] - Daye Co. is responding to the EU's anti-dumping investigation on Chinese lawnmowers, adjusting its overseas production structure and integrating resources to mitigate impacts [4]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotech, has received inclusion in the breakthrough therapy designation for its independently developed drug, Surulitinib injection, for the treatment of gastric cancer, which is a significant milestone as no PD-1 targeted monoclonal antibody has been approved for this indication globally [1] Group 1 - The drug Surulitinib (marketed as Hanshuang in China) is intended for use in combination with chemotherapy for neoadjuvant/adjuvant treatment of gastric cancer [1] - The inclusion in the breakthrough therapy program is expected to expedite the review and market launch process for this indication in China [1] - As of the announcement date, there are no approved PD-1 targeted monoclonal antibodies for neoadjuvant/adjuvant treatment of gastric cancer worldwide [1]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotech Co., Ltd., has received inclusion of its independently developed drug, Surufatinib injection, in the breakthrough therapy designation program for the treatment of gastric cancer in combination with chemotherapy [1] Summary by Relevant Sections - **Drug Approval and Indications** - Surufatinib injection has been approved for marketing in multiple countries/regions including China, the EU, the UK, Indonesia, Cambodia, Thailand, Malaysia, Singapore, and India [1] - In China, the approved indications include first-line treatment for squamous non-small cell lung cancer, extensive small cell lung cancer, esophageal squamous cell carcinoma, and non-squamous non-small cell lung cancer [1]

Core Viewpoint - Fosun Pharma's subsidiary, Shanghai Fuhong Hanlin Biotechnology Co., Ltd., has received inclusion of its independently developed drug, Surulitinib Injection, in the breakthrough therapy program for the treatment of gastric cancer in China [1][2] Group 1: Drug Development and Approval - Surulitinib is an innovative anti-PD-1 monoclonal antibody developed by the group [2] - As of November 20, 2025, the drug has been approved for marketing in multiple countries/regions including China, the EU, the UK, Indonesia, Cambodia, Thailand, Malaysia, Singapore, and India [2] - In China, the approved indications include first-line treatment for squamous non-small cell lung cancer (sq-NSCLC), extensive-stage small cell lung cancer (ES-SCLC), esophageal squamous cell carcinoma (ESCC), and non-squamous non-small cell lung cancer (nsq-NSCLC) [2] Group 2: Regulatory Designations and Clinical Trials - The drug has received orphan drug designation from regulatory authorities in the US, EU, Switzerland, and South Korea [2] - Multiple combination therapies involving Surulitinib are currently undergoing clinical trials in various countries and regions, targeting indications such as lung cancer, esophageal cancer, head and neck squamous cell carcinoma, colorectal cancer, and gastric cancer [2]

Group 1 - Company Yiwei Lithium Energy signed a procurement framework agreement with Simor International on November 20, 2025, for the continuous supply of battery cells and other products as raw materials, with actual amounts to be determined by future orders [1] - ST Huamei's stock is under "double risk" warning due to an inability to express an opinion in its 2024 financial report, with a recovery of 1.567 billion yuan in occupied funds as of August 15, 2025, and the stock remains under risk warning with a 5% trading limit [2] - Wuzhou Transportation received a regulatory warning from the Shanghai Stock Exchange for non-compliance in accounting practices and failure to fulfill integrity checks for executives, requiring a rectification report [3] Group 2 - Wenkang Co.'s deputy general manager Qin Guofen is under investigation, but the company states this will not significantly impact its operations [4] - Fosun Pharma's subsidiary Shanghai Fuhong Hanlin's drug, SLR-121, has been included in the breakthrough therapy designation for gastric cancer treatment, marking a significant milestone as no PD-1 monoclonal antibody has been approved for this indication globally [5] - Shandong Steel's subsidiary plans to apply for bankruptcy liquidation, which is expected to increase the parent company's net profit by 15.88 million yuan, allowing the company to focus on its core business [6] Group 3 - Zhuhai Ming Technology established a new subsidiary, Shenzhen Zhixian Robotics Co., with a registered capital of 50 million yuan, in which Zhuhai Ming holds a 50% stake [7] - Spring Airlines conducted its first share buyback, repurchasing 35,800 shares for a total of 1.9997 million yuan, representing 0.0037% of its total share capital [9] - Donghua Software's controlling shareholder reduced his stake by 1%, bringing his direct holding down to 10.90%, in line with a previously disclosed plan [11] Group 4 - Changshu Bank's executives plan to increase their holdings by at least 550,000 shares over the next six months, with specific minimum amounts for each executive [12] - Nanfeng Co. won contracts worth 45.7 million yuan and 47.17 million yuan for HVAC systems, with delivery dates set for July and August 2027, respectively [14] - Huakang Clean's bid for the Keqiao Future Medical Center purification system project was successful, with a bid amount of 176 million yuan [15] - Qinglong Pipe Industry secured a contract worth 294 million yuan for a pipe procurement project, expected to impact its performance from 2026 to 2030 [16] - China Nuclear Engineering signed new contracts totaling 123.84 billion yuan and achieved revenue of 81.334 billion yuan as of October 2025 [17]

香港交易及結算所有限公司及香港聯合交易所有限公司對本公告的內容概不負責，對其準確性或完整性亦不 發表任何聲明，並明確表示，概不對因本公告全部或任何部份內容而產生或因倚賴該等內容而引致的任何損 失承擔任何責任。 上 海 復 星 醫 藥（ 集 團 ）股 份 有 限 公 司 Shanghai Fosun Pharmaceutical (Group) Co., Ltd.* （於中華人民共和國註冊成立的股份有限公司） （股份代號：02196） 海外監管公告 本公告乃根據香港聯合交易所有限公司證券上市規則第13.10B條而作出。 茲載列上海復星醫藥（集團）股份有限公司（「本公司」）在上海證券交易所網站刊登的《關於 控股子公司藥品納入突破性治療藥物程序的提示性公告》，僅供參閱。 承董事會命 中國，上海 2025 年1 1 月2 0 日 於本公告日期，本公司之執行董事為陳玉卿先生、關曉暉女士、文德鏞先生及王可心先生；本公司之非執行 董事為陳啟宇先生及潘東輝先生；本公司之獨立非執行董事為余梓山先生、王全弟先生、Chen Penghui先生 及楊玉成先生；以及本公司之職工董事為嚴佳女士。 * 僅供識別 上海復星醫藥（集團）股份有 ...